MedTrace Logo

Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

NCT00826449 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2016-06-28

Study results available
· View outcomes & findings →

Summary

The goal of the Phase I portion of this study is to find the highest tolerable dose of the combination of dasatinib and erlotinib hydrochloride that can be given to patients with advanced solid tumors.

The goal of the Phase II portion of this study is to learn if this combination is effective when given to patients with non-small cell lung cancer.

The safety of this combination will be studied in both phases.

Conditions

Interventions

DRUG

Dasatinib

Starting dose of 70 mg by mouth daily for 21 day cycle.

DRUG

Erlotinib

150 mg by mouth daily every 21 day cycle.

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • OSI Pharmaceuticals

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Faye M. Johnson, MD, PhD, BS · UT MD Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00826449 on ClinicalTrials.gov